Aptinyx
Evanston
Illinois
United States
127 articles with Aptinyx
-
Aptinyx's NYX-458 fell short of the primary endpoint in a Phase II trial of patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
-
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
2/27/2023
Aptinyx Inc. (Nasdaq: APTX) today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
-
Aptinyx to Present at the SVB Securities Global Biopharma Conference
1/31/2023
Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
-
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
11/10/2022
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience.
-
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
11/8/2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
-
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
11/3/2022
Aptinyx Inc. today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD).
-
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
10/18/2022
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.
-
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
8/25/2022
Aptinyx Inc. today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
-
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
-
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
8/12/2022
Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.
-
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
8/4/2022
Aptinyx Inc. (Nasdaq: APTX), today reported financial results for the second quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
-
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
7/15/2022
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.
-
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
6/22/2022
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference.
-
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
5/18/2022
Aptinyx Inc. announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022.
-
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
5/17/2022
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.
-
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
5/12/2022
Aptinyx Inc. reported financial results for the first quarter of 2022 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.
-
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
4/29/2022
Aptinyx Inc. today presented data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28 – April 30, 2022 in New Orleans, Louisiana.
-
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
4/27/2022
Aptinyx Inc. today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights.
-
Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783
4/20/2022
Aptinyx Inc. announced that data from preclinical studies evaluating NYX-783, a novel NMDA receptor positive allosteric modulator, in models of post-traumatic stress disorder were published in the journal, Molecular Psychiatry.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.